Promore Pharma has two programs undergoing clinical development; PXL01, aimed for prevention of post-surgical adhesions and dermal scarring, is being prepared for Phase III trials on patients undergoing flexor tendon repair surgery in the hand. LL-37 is being developed as a chronic leg ulcers treatment, is being prepared for Phase IIb in patients with venous leg ulcers.
The pharmaceutical candidates are therapeutic peptides that are derived from human sequences that are part of innate immune system, having multiple biological functions and properties. PXL01 and LL-37 have proven efficacy from both non-clinical and clinical studies. Additionally, PharmaResearch Products Ltd., a strategic partner of Promore Pharma, has acquired a license to develop a medical device product based on PXL01 for prevention of adhesions after spinal surgery, aimed for certain markets in Asia.